Breakfast breakthrough? study tests easier, cheaper dosing for costly cancer drug
NCT ID NCT05263245
Summary
This study tested if taking the kidney cancer drug cabozantinib with a light breakfast, instead of on an empty stomach, changes how much drug gets into the body. Researchers wanted to see if this could lead to new dosing schedules that might reduce side effects like nausea and diarrhea, and potentially lower costs. They measured drug levels in the blood of 12 patients taking the drug both ways.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Erasmus Medical Center
Rotterdam, South Holland, 3015 GD, Netherlands
-
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333 ZA, Netherlands
Conditions
Explore the condition pages connected to this study.